TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress
ACCESSWIRE - Tue Feb 25, 8:42AM CST
SEATTLE, WA / Feb 25, 2014 / ACCESSWIRE / TapImmune Inc. (OTCQB:TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.
Janssen Announces New Group Targeting Unmet Global Health Needs
PR Newswire - Wed Jan 22, 7:15AM CST
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced the formation of Janssen Global Public Health (Janssen GPH), an important new group unifying Janssen's commitment to research, develop, and deliver transformational medicines to address the world's greatest unmet public health needs. Janssen GPH will align the company's groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.
OTC Signal Daily Stock Watch - TapImmune Inc. (OTCBB: TPIV)
WorldStockWire - Mon Oct 14, 12:45AM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Tapimmune Announces Development of Advanced Immunotherapeutic Vaccine Expression and Delivery System
ACCESSWIRE - Wed Oct 09, 9:20AM CDT
Seattle, WA. / October 9, 2013 / ACCESSWIRE / TapImmune Inc. (OTCQB: TPIV) is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system.
TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations
ACCESSWIRE - Wed Jun 26, 10:31AM CDT
Seattle, WA, June 26, 2013 (eTeligis via ACCESSWIRE) -- TapImmune (OTCQB: TPIV)
TapImmune Inc names Sherry Grisewood to board
M2 - Thu Mar 21, 9:37AM CDT
Vaccine company TapImmune Inc (OTC BB:TPIV) revealed on Wednesday the appointment of Sherry Grisewood, CFA to the board of directors.
TapImmune Announces the Appointment of Sherry Grisewood to the Board of Directors
PR Newswire - Wed Mar 20, 8:00AM CDT
TapImmune Inc. (OTCQB: TPIV) has pleasure in announcing the appointment of Sherry Grisewood, CFA to the Board of Directors. She has over 25 years securities industry experience in a range of investment banking, advisory and research-related activities. She currently has a senior banking and banking analytical role at Dawson James Securities. Prior to joining Dawson James, she was Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. Sherry served as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks over the prior 12 year period. She has participated in over 50 transaction-related projects worldwide involving initial public offerings, secondary offerings, PIPE's, private equity, M&A and licensing transactions in the life sciences sector. Prior to consulting for investment banks, Sherry served as Director of Research for several mid-tier brokerage companies and a leading independent
TapImmune Inc. to Present at the Florida Road Show Conference on March 14, 2013
PR Newswire - Wed Mar 13, 8:00AM CDT
TapImmune Inc. ("TapImmune" or the "Company") (OTCQB: TPIV), an immunotherapy company focused on the development of novel peptide and gene-based vaccine technologies, announced today that the Company will present at the Florida Road Show Conference in Boca Raton, Florida on Thursday, March 14, 2013. This conference, hosted by Corporate Roadshow and Undiscovered Equities, will feature presentations by CEOs and CFOs of promising emerging growth companies to an invited audience of investment bankers, analysts, hedge-fund managers, top brokers and accredited investors.
OTC Signal Daily Stock Watch
WorldStockWire - Tue Jan 22, 11:28PM CST
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com
Positive Interim Safety Analysis Achieved in Breast Cancer Patients Treated with HER2/neu Antigens
PR Newswire - Wed Jan 09, 8:00AM CST
TapImmune Inc. (OTCBB: TPIV) has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events. As a result treatment of the remaining 17 patients in the Phase I study, being conducted at Mayo Clinic, Rochester, MN will progress. The proprietary HER2/neu Class II antigens, discovered by Keith Knutson Ph.D. and colleagues at Mayo Clinic, show high affinity binding to human MHC proteins for ~84% of the population making it potentially applicable to a broad spectrum of HER2/neu patients compared to other approaches. The Phase I trial is being carried out in breast cancer patients who finished standard Herceptin®-based therapy and are at risk of disease recurrence. The primary endpoints of the study are safety and immunogenicity. Details of the Phase I trial can be found at http://clinicaltrials.gov. TapImmune is sponsoring the Phase I study and has an Exclusive Option to Li